Amgen buys ChemoCentryx for $3.7 billion, or $52 per share. ChemoCentryx developed the drug TAVNEOS to treat ANCA-associated vasculitis. Its U.S. sales in the first quarter of 2022, its first full quarter of sales, were $5.4 million. TAVNEOS is also already approved in major markets outside the U.S., including the European Union and Japan. The deal is scheduled to close in the fourth quarter of 2022.
Amgen buys ChemoCentryx for $3.7 billion, or $52 per share. ChemoCentryx developed the drug TAVNEOS to treat ANCA-associated vasculitis. Its U.S. sales in the first quarter of 2022, its first full quarter of sales, were $5.4 million. TAVNEOS is also already approved in major markets outside the U.S., including the European Union and Japan. The deal is scheduled to close in the fourth quarter of 2022. 
investors.amgen.com
English (US) 